Perseus Proteomics, Inc. (JP:4882) has released an update.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Perseus Proteomics, Inc. has announced the publication of an abstract for its radiopharmaceutical therapy, PPMX-T002, aimed at treating solid cancers, at the EANM ’24 Annual Congress. PPMX-T002 targets the cadherin 3 protein on various solid tumors and has shown enhanced efficacy in preclinical trials when using Actinium 225 compared to Yttrium 90.
For further insights into JP:4882 stock, check out TipRanks’ Stock Analysis page.